中华精神科杂志
中華精神科雜誌
중화정신과잡지
CHINESE JOURNA OF PSYCHIATRY
2009年
4期
224-227
,共4页
陈海支%钮富荣%钱敏才%俞柏润%沈鑫华%杨身国%钟华%黄卫权%杨胜良%沈仲夏
陳海支%鈕富榮%錢敏纔%俞柏潤%瀋鑫華%楊身國%鐘華%黃衛權%楊勝良%瀋仲夏
진해지%뉴부영%전민재%유백윤%침흠화%양신국%종화%황위권%양성량%침중하
精神分裂症%高催乳素血症%利哌立酮%阿立哌唑
精神分裂癥%高催乳素血癥%利哌立酮%阿立哌唑
정신분렬증%고최유소혈증%리고립동%아립고서
Schizophrenia%Hyperprolactinmia%Risperidone%Aripiprazole
目的 探讨加用阿立哌唑对利培酮所致的首次发病的男性精神分裂症患者高催乳素血症的影响及安全性.方法 将80例男性精神分裂症首次发病住院患者随机分为研究组(40例)和对照组(40例).使用利培酮治疗4周后催乳素水平≥60 μg/L的患者,在维持原有治疗不变的基础上,研究组加用阿立哌唑5 mg/d,对照组加用安慰剂治疗,总疗程12周,研究周期8周(第4～12周末).于治疗第0,4,8,12周末检测血清催乳素含量,并用阳性和阴性症状评定量表(PANSS)、治疗中需要处理的不良反应量表(TESS)进行评定.结果 研究组治疗第12周末血清催乳素[(25±7)μg/L]较第4周末[(76±17)μg/L]下降,差异有统计学意义(t=15.87;P＜0.01).对照组治疗第12周末催乳素[(79±13)μg/L]与第4周末[(78±15)μg/L]比较,差异无统计学意义(t=0.72;P＞0.05);治疗第12周末催乳素下降率为(66 ±11)%、正常率为67.6%,均高于对照组[分别为(-1±18)%、6.5%](P均＜0.01).两组患者治疗前后比较,PANSS评分总分及分量表分均明显下降(P均＜0.01);在治疗第12周未两组之间各项评分比较,筹异均无统计学意义(t=0.40,0.76,0.22,0.88;P均＞0.05).治疗第12周未研究组TESS评分(4.8±4.3)与对照组(4.5±3.9)的差异无统计学意义(t=0.29;P＞0.05).结论阿立哌唑治疗利培酮所致精神分裂症男性患者高催乳素血症有效,安全.
目的 探討加用阿立哌唑對利培酮所緻的首次髮病的男性精神分裂癥患者高催乳素血癥的影響及安全性.方法 將80例男性精神分裂癥首次髮病住院患者隨機分為研究組(40例)和對照組(40例).使用利培酮治療4週後催乳素水平≥60 μg/L的患者,在維持原有治療不變的基礎上,研究組加用阿立哌唑5 mg/d,對照組加用安慰劑治療,總療程12週,研究週期8週(第4～12週末).于治療第0,4,8,12週末檢測血清催乳素含量,併用暘性和陰性癥狀評定量錶(PANSS)、治療中需要處理的不良反應量錶(TESS)進行評定.結果 研究組治療第12週末血清催乳素[(25±7)μg/L]較第4週末[(76±17)μg/L]下降,差異有統計學意義(t=15.87;P＜0.01).對照組治療第12週末催乳素[(79±13)μg/L]與第4週末[(78±15)μg/L]比較,差異無統計學意義(t=0.72;P＞0.05);治療第12週末催乳素下降率為(66 ±11)%、正常率為67.6%,均高于對照組[分彆為(-1±18)%、6.5%](P均＜0.01).兩組患者治療前後比較,PANSS評分總分及分量錶分均明顯下降(P均＜0.01);在治療第12週未兩組之間各項評分比較,籌異均無統計學意義(t=0.40,0.76,0.22,0.88;P均＞0.05).治療第12週未研究組TESS評分(4.8±4.3)與對照組(4.5±3.9)的差異無統計學意義(t=0.29;P＞0.05).結論阿立哌唑治療利培酮所緻精神分裂癥男性患者高催乳素血癥有效,安全.
목적 탐토가용아립고서대리배동소치적수차발병적남성정신분렬증환자고최유소혈증적영향급안전성.방법 장80례남성정신분렬증수차발병주원환자수궤분위연구조(40례)화대조조(40례).사용리배동치료4주후최유소수평≥60 μg/L적환자,재유지원유치료불변적기출상,연구조가용아립고서5 mg/d,대조조가용안위제치료,총료정12주,연구주기8주(제4～12주말).우치료제0,4,8,12주말검측혈청최유소함량,병용양성화음성증상평정량표(PANSS)、치료중수요처리적불량반응량표(TESS)진행평정.결과 연구조치료제12주말혈청최유소[(25±7)μg/L]교제4주말[(76±17)μg/L]하강,차이유통계학의의(t=15.87;P＜0.01).대조조치료제12주말최유소[(79±13)μg/L]여제4주말[(78±15)μg/L]비교,차이무통계학의의(t=0.72;P＞0.05);치료제12주말최유소하강솔위(66 ±11)%、정상솔위67.6%,균고우대조조[분별위(-1±18)%、6.5%](P균＜0.01).량조환자치료전후비교,PANSS평분총분급분량표분균명현하강(P균＜0.01);재치료제12주미량조지간각항평분비교,주이균무통계학의의(t=0.40,0.76,0.22,0.88;P균＞0.05).치료제12주미연구조TESS평분(4.8±4.3)여대조조(4.5±3.9)적차이무통계학의의(t=0.29;P＞0.05).결론아립고서치료리배동소치정신분렬증남성환자고최유소혈증유효,안전.
Objective To investigate the efficacy and safety of aripiprazole on the hyperprolactinmia induced by risperidone in the first-episode patients with male schizophrenia.Methotis All 80 first-episode male inpatients who had received no antipsychotic medication were randomly assigned to research group(n=40)and control group(n=40).All the patients were treated with risperidone for 4 weeks.and then patients whose prolactin level reached to 60μg/L were administered additionaJ aripiprazole 5 mg daily or placebo for 12 weeks.The plasma prolactin(PRL)level was measured at weeks 0,4,8,12,and the Positive and Negative Syndrome Scale(PANSS)and Treatment Emergent Symptom Scale(TESS)were assessed.Results Plasma prolactin levels were significantly reduced at the end of the study compared with the 4th weekend[(25±7)μg/L vs.(76±17)μg/L]in research group(t=15.87;P＜0.01),while there were no significant difference between the 4th weekend and post treatment in control group[ (78±15)μg/L vs.(79±13)μg/L](t=0.72;P＞0.05).At week 12,the decline rate and the normal ratio of plasma prolactin levels were significantly higher in aripiprazole group[(66±11)%,67.6%]than that in control group[(-1±18)%,6.5%](both P＜0.01).Compared with the baseline,the PANSS score showed significant reduction in both groups at the end of the study [(38.29±5.67)vs.(83.68 ±12.56)],[(39.71±7.80)vs.(83.81±13.47)](both P＜0.01),and there were no significant differences on the PANSS score between both groups(P＞0.05).The incidence of side effects showed no significant difference between aripiprazole and control group(P＞0.05).Conclusion The results indicate that aripiprazole may be effective and safe for the treatment of male schizophrenics with risperidone induced hyperprolactinemia.
